Clinical Take-Home Messages GLP-1RAs are no longer diabetes-only drugs. They are becoming: Obesity therapies Cardiovascular protective agents Anti-inflammatory therapies Neuroprotective candidates Metabolic disease modifiers Conclusion We are witnessing a historic transition in medicine
Fat loss also improved relative to monotherapy, with 17.8% and 15.1% greater reductions observed in the lower- and higher-dose arms, respectively
Now until the end of July enjoy specials on the following: TruSculpt iD $950 off an ab treatment Botox $12/unit Dysport $4/unit $75 off any filler Champagne Facial with Diamond Glow-$150 Call 713-622-2277 to make a FREE consult Care Credit to offer 0% interest financing for up to 24 months
The needle-free medication formats, including drops, lozenges, and the oral Wegovy pill, make Shed particularly relevant for people who want GLP-1 treatment but are averse to injections
Lipid improvements, including triglyceride reductions of 20 to 30 percent and modest LDL decreases, typically manifest by 16 to 20 weeks
How the antioxidant role of -glutamylcysteine is regulated under (patho) physiological conditions now needs to be deciphered